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Mean viral loads for patients with pandemic (H1N1) 
2009 were ≈1 log10 times lower than those for patients with 
seasonal inﬂ  uenza within the ﬁ  rst week after symptom on-
set. Neither pandemic nor seasonal inﬂ   uenza viral loads 
correlated with clinical severity of illness. No correlation was 
found between viral loads and concurrent illness.
A
lthough clinical characteristics of pandemic (H1N1) 
2009 have been well documented (1,2), fewer speciﬁ  c 
virologic comparisons with seasonal inﬂ  uenza have been 
studied in hospitalized patients (3). Studies of other inﬂ  u-
enza virus infections in humans suggest that host immune 
responses play a major role in determining clinical out-
comes (4,5). We describe the initial viral loads for patients 
infected with pandemic (H1N1) 2009 and seasonal (H1 and 
H3) inﬂ  uenza viruses and their correlation with various as-
pects of signs and symptoms at admission to the National 
University Hospital (NUH) in Singapore.
The Study
The study consisted of patients seen at NUH during 
May–November 2009 as emergency admissions, outpa-
tients, or inpatients whose nasopharyngeal swabs submitted 
for routine diagnostic testing were positive for seasonal in-
ﬂ  uenza virus A (H1 and H3) or pandemic inﬂ  uenza A virus 
(H1N1) 2009. From samples taken before treatment was 
begun, we identiﬁ  ed 578 patients with pandemic (H1N1) 
2009 and 88 patients with seasonal inﬂ  uenza (11 H1 and 77 
H3). Clinical characteristics of some of these patients have 
been described elsewhere (2). Local ethics approval (ref. 
no. B/09/360) was granted for this study.
Age, sex, and clinical information (i.e., days after 
onset of symptoms, comorbidities, clinical severity) were 
obtained from patient records. Comorbidities were deﬁ  ned 
as >1 of the conditions listed in Table 1. Clinical sever-
ity was deﬁ  ned as follows: mild, patients well enough to 
be treated as outpatients; moderate, patients ill enough to 
warrant hospital admission; severe, hospitalized patients 
who died or who required intensive or high-dependency 
care. In-house quantitative assays (online Technical Ap-
pendix, www.cdc.gov/EID/content/17/2/285-Techapp.
pdf) were performed on archived samples previously 
tested as positive for pandemic (H1N1) 2009 and reported 
elsewhere (6).
Viral loads of hemagglutinin (HA) and nucleoprotein 
(NP) for pandemic (H1N1) 2009 ranged from 102 to 109 
RNA copies/mL of virus transport medium (mean 105–107 
RNA copies/mL). Seasonal inﬂ  uenza viral loads ranged 
from 103 to 1010 RNA copies/mL (mean 106–108 RNA cop-
ies/mL for seasonal inﬂ  uenza subtype H3 and mean 105 to 
107 RNA copies/mL for seasonal inﬂ  uenza H1). Viral loads 
decreased with time after onset of symptoms from date the 
patient sought care at NUH in patients with pandemic or 
seasonal inﬂ  uenza (Figure 1).
Because of the small number of patients with seasonal 
inﬂ  uenza H1, further analysis for seasonal inﬂ  uenza was 
limited to H3. Patients infected with pandemic (H1N1) 
2009, compared with those having seasonal inﬂ  uenza H3, 
were younger (p<0.0001), and a higher proportion had co-
morbidities (p = 0.0068; Table 1).
 For the 578 pandemic inﬂ  uenza cases, the multiple 
analysis of variance showed that viral loads were associ-
ated with number of days after symptom onset from date 
of presentation (p<0.0001) and with age (p = 0.0112) (Fig-
ure 2, panel A; Table 2). For the 77 seasonal inﬂ  uenza H3 
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Figure 1. Viral loads (in RNA copies/mL) in patients with pandemic 
(H1N1) 2009 (NP) and seasonal H1 and H3 (MP) inﬂ  uenza at time 
patient sought hospital care against days after symptom onset. 
Vertical bars indicate ±1 SD. Line plots are slightly offset with 
respect to each other along the time axis to allow the SD bars to be 
seen clearly. NP, nucleoprotein; MP, matrix protein.cases, the analysis of variance showed that days after onset 
of symptoms from date of presentation (p = 0.0223) and 
presence of any comorbidities (p = 0.0249) signiﬁ  cantly af-
fected viral loads (Table 2). Viral loads for seasonal inﬂ  u-
enza were lower in patients with than without comorbidi-
ties (Figure 2, panel B).
Conclusions
One of our most striking ﬁ  ndings was that the mean 
viral loads of patients visiting NUH were ≈1 log10 higher 
for seasonal than for pandemic inﬂ  uenza (Figure 1). This 
difference persisted even after we adjusted for age. Another 
study demonstrated that within the ﬁ  rst 3 days after symp-
tom onset, historical mean viral loads of seasonal inﬂ  uenza 
exceed those of the contemporary pandemic virus by 1–2 
log10 (3). However, a limitation of that study is its use of 
viral load data for seasonal inﬂ  uenza that was historical 
rather than obtained contemporaneously with the data for 
pandemic (H1N1) 2009.
Approximately 30%–50% of inﬂ  uenza case-patients 
may be asymptomatic (7), and although the correlation be-
tween viral load and clinical symptoms is not well estab-
lished, a viral load threshold may exist below which most 
persons have no clinical symptoms (although individual 
variation will always exist). Our analysis suggests that if 
such a threshold exists, it is lower for novel than for season-
al inﬂ  uenza viruses. For a direct virus-mediated pathologic 
process, this hypothesis may be understandable, given the 
lower prevalence of preexisting (and therefore potentially 
partially protective) cross-reactive immunity for this novel 
virus (8–10).
Viral loads for both pandemic (H1N1) 2009 and sea-
sonal inﬂ  uenza tend to decrease with time after symptom 
onset (Figure 1). Larger studies are needed to conﬁ  rm the 
more rapid decline of seasonal inﬂ  uenza H1 than of H3 vi-
ral loads. In addition, younger age groups had signiﬁ  cant-
ly higher viral loads for pandemic (H1N1) 2009 (Figure 
2, panel A), which may not be surprising given that this 
Southeast Asian population appears to have little or no pre-
existing speciﬁ  c or cross-reacting antibodies to this novel 
virus (9,10).
Two ﬁ  ndings are perhaps the most surprising of this 
analysis. First, we found no signiﬁ  cant correlation between 
pandemic (H1N1) 2009 or seasonal inﬂ  uenza viral loads 
and clinical severity of illness (Table 2). Second, pandemic 
(H1N1) 2009 viral loads in infected patients with and with-
out preexisting comorbidities did not differ signiﬁ  cantly, 
although a signiﬁ  cant difference was found for seasonal 
inﬂ  uenza (Figure 2, panel B; Table 2). We offer some pos-
sible explanation for these ﬁ  ndings but note that these in-
ﬂ  uenza viral loads have been measured in respiratory sam-
ples. These samples are peripheral types of specimens that 
may not necessarily directly affect, or be directly affected 
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Figure 2. A) Proﬁ   le plot and multivariate comparisons of the 
estimated nucleoprotein viral loads of pandemic (H1N1) 2009, by 
patient age group, against days from symptom onset in the ﬁ  nal 
multiple analysis of variance model. B) Proﬁ  le plot and comparisons 
of the estimated matrix protein viral loads of seasonal inﬂ  uenza 
H3 by the presence or absence of comorbidities against days from 
symptom onset in the ﬁ  nal analysis of variance model. Pandemic and Seasonal Inﬂ  uenza Viral Loads
by, many of the preexisting comorbidities that involve non-
respiratory systems, unless their management involves, for 
example, some sort of immunosuppressive therapy.
A main limitation of this study is that these viral load 
measurements were performed on only 1 acute diagnostic 
sample from each patient at admission before treatment 
with oseltamivir; therefore, determining how these viral 
loads would have changed later during the natural course 
of the infection was not possible. Also, some of the patient 
categories (Tables 1, 2) contained relatively few patients, 
e.g., the relatively low number of severe cases (Tables 1, 
2), which may have limited the statistical signiﬁ  cance of 
some correlations. Finally, although inﬂ  uenza viral loads in 
various types of respiratory samples are now often report-
ed (3,6), these are heterogeneous, peripheral samples, and 
such viral loads may vary considerably in the same patient 
during a single day, depending on individual host immune 
responses.
If human illness caused by inﬂ  uenza virus infections 
is mediated by host immune responses (4,5), then a more 
vigorous, primary immune response in the immunologi-
cally naive, otherwise healthy younger population against 
the pandemic (H1N1) 2009 virus may also contribute to 
the degree of clinical illness. The interplay between a di-
rect viral pathologic process and a host immune-mediated 
pathologic process is probably unique to each person. Some 
recent studies investigating cytokine responses in persons 
with acute pandemic (H1N1) 2009 infections had contrast-
ing ﬁ  ndings (11–13), although postmortem investigations 
of some fatal cases of pandemic (H1N1) 2009 infection 
found substantial inﬂ   ammation, which supports an im-
mune-mediated pathologic process for at least in these cas-
es (14). Similarly, for the more well-established seasonal 
H3 inﬂ  uenza (to which most persons have had many years 
of exposure) more well-established, robust, yet sufﬁ  ciently 
individually different patterns of homologous and heterolo-
gous immune responses may contribute more (compared 
with similar responses to pandemic [H1N1] 2009) to the 
different degrees of clinical illness in infected persons with 
different combinations of comorbidities.
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Table 1. Comparison of baseline characteristics between patients with pandemic (H1N1) 2009 and seasonal influenza H3 infection,
Singapore, May–November 2009 
Characteristic
Pandemic (H1N1) 2009, no. (%), 
n = 578 
Seasonal influenza H3, no. (%), 
n = 77  p value 
Age, y  <0.0001 
  0–4  69 (11.9)  7 (9.1) 
  5–14  144 (24.9)  11 (14.3) 
  15–34  250 (43.3)  28 (36.4) 
  35–54  72 (12.5)  13 (16.9) 
 > 55 43 (7.4)  18 (23.4) 
Female sex  275 (47.6)  41 (53.2)  0.3959 
Comorbidities* 262 (45.3)  22 (28.6)  0.0068 
  Asthma  120 (20.8)  7 (9.1)  0.0137 
  Chronic lung disease  15 (2.6)  3 (3.9)  0.4584 
  Cardiac disease  21 (3.6)  4 (5.2)  0.5214 
  Chronic renal failure  21 (3.6)  2 (2.6)  1.0000 
  Chronic liver disease  11 (1.9)  0 0.6275 
  Cerebrovascular disease  9 (1.6)  2 (2.6)  0.3776 
  Neoplasms  22 (3.8)  3 (3.9)  1.0000 
  Diabetes  41 (7.1)  5 (6.5)  1.0000 
  Pregnancy  39 (6.7)  2 (2.6)  0.2115 
  Immunocompromised  27 (4.7)  2 (2.6)  0.5621 
  Receipt of steroid medication  23 (4.0)  1 (1.3)  0.3429 
  Autoimmune disease  14 (2.4)  1 (1.3)  1.0000 
  Neurocognitive disease  12 (2.1)  1 (1.3)  1.0000 
  Neuromuscular disease  2 (0.3)  0 1.0000 
Premitigation phase  104 (18.0)  51 (66.2)  <0.0001 
Clinical severity†  0.0462
  Severe cases‡  23 (4.9)  1 (3.8) 
  Hospitalized cases§  222 (46.8)  6 (23.1) 
  Outpatient only  229 (48.3)  19 (73.1) 
*Patient had >1 of the conditions listed. 
†Analysis was limited to patients in whom influenza were diagnosed during the mitigation phase (n = 474 for pandemic and n = 26 for H3 seasonal 
influenzas). Singapore switched from premitigation (i.e., containment) to mitigation management protocols on July 8, 2009, which altered how patient 
treatment with oseltamivir was initiated. However, this transition does not affect the results shown above because none of the patients were undergoing 
treatment when these first diagnostic samples were taken. 
‡Patients requiring intensive or high-dependency care or who died. 
§Patients requiring hospitalization because of clinical conditions but not intensive or high-dependency care. P.A.T. was supported by the Asia Paciﬁ  c Inﬂ  uenza Advisory 
Committee and MerLion Pharma; lecture fees from Pﬁ  zer, Novar-
tis, Wyeth, and International Business Communications Asia; and 
grant support from Baxter, Interimmune, and Adamas.
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Table 2. Analysis of pandemic (H1N1) 2009 (HA and NP) and seasonal H3 (MP) viral loads with clinical parameters, Singapore, May–
November 2009* 
Characteristic
Pandemic influenza  Seasonal H3 influenza 
No.
HA viral load, log10
copies/mL, mean (SD) 
NP viral load, log10
copies/mL, mean (SD)
MANOVA 
p value†  No.




Time from symptom onset, d  <0.0001  0.0223 
  1–2  416 6.49 (1.44)  6.49 (1.38)  53 8.12 (1.43) 
  3–4  114 6.18 (1.39)  6.16 (1.40)  20 7.27 (1.31) 
  5–7  48 5.33 (1.21)  5.31 (1.23)  4 6.76 (1.22) 
Age, y  0.0112‡  0.9652‡ 
  0–4  69 6.46 (1.40)  6.45 (1.39)  7 7.66 (0.75) 
  5–14  144 6.62 (1.36)  6.65 (1.26)  11 7.93 (1.38) 
  15–34  250 6.34 (1.48)  6.33 (1.43)  28 7.88 (1.66) 
  35–54  72 5.85 (1.46)  5.88 (1.41)  13 7.99 (1.04) 
 > 55 43 5.88 (1.41)  5.83 (1.50)  18 7.63 (1.66) 
Sex 0.3018‡ 0.3883‡ 
  F  275 6.23 (1.49)  6.26 (1.38)  41 7.68 (1.52) 
  M  303 6.42 (1.41)  6.39 (1.43)  36 8.00 (1.35) 
Comorbidities 0.9967‡ 0.0249‡ 
  Yes  262 6.35 (1.49)  6.35 (1.44)  22 7.23 (1.53) 
  No  316 6.31 (1.42)  6.31 (1.39)  55 8.07 (1.35) 
Clinical severity§ 
  Severe  23 5.97 (1.76)  5.98 (1.84) 
  Hospitalized  222 6.44 (1.49)  6.42 (1.43)  7¶ 7.55 (1.06) 
  Outpatient  229 6.29 (1.45)  6.30 (1.40)  19 7.25 (1.54) 
*HA, hemagglutinin; NP, nucleoprotein; MP, matrix protein; MANOVA, multiple analysis of variance; ANOVA, analysis of variance. 
†Wilks Lambda statistics. 
‡Effect of days from symptom onset adjusted. 
§Analysis included patients who sought care during the mitigation phase only (n = 474 for pandemic and n = 26 for H3 seasonal influenzas). Singapore 
switched from premitigation (i.e., containment) to mitigation management protocols on July 8, 2009, which altered how patient treatment with oseltamivir 
was initiated. However, this transition does not affect the results shown above because none of the patients were undergoing treatment when these first 
diagnostic samples were taken. 
¶Includes 1 severe case. Pandemic and Seasonal Inﬂ  uenza Viral Loads
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